NeoGenomics Laboratories
Cancer diagnostics testing and pharma services
Customer Advocate 1 - Client Services
More locations: Fort Myers, FL, USA | Carlsbad, CA, USA
About the job
- A high school diploma or equivalent.
- Excellent typing and data entry skills.
- Proficiency with Microsoft Office programs and database management.
- Experience handling multiple projects.
- Strong organizational, attention-to-detail, and follow-up skills.
- Ability to maintain production and quality standards in a dynamic environment.
- Ability to stand, sit, walk, bend, reach, perform manual manipulation, and lift up to 15 pounds.
- Receive and initiate telephone calls from and to customers and sales representatives.
- Report test results accurately to the appropriate person.
- Add and cancel tests.
- Provide specimen requirements and research test availability.
- Provide testing fees.
- Perform basic problem solving.
- Order supplies.
- Review pending lists.
- Apply a solid understanding of logistics.
- Triage calls and forward them to the correct individual or department.
- Resolve client and case concerns in a timely manner and follow through until incidents are complete.
- Provide results to clients in accordance with department standard operating procedures while ensuring the privacy and confidentiality of communications.
- Assess and respond to situations where standard protocol has failed and work with other departments to resolve customer or sales issues.
- Document all phone calls and emails in Salesforce.com.
- Provide appropriate and timely follow-up with clients.
- Monitor service levels, minimize abandoned calls and long wait times, and support improvements in department quality and productivity.
- Assist with identifying client trends involving critical issues for management and sales.
- Make necessary communications to clients within the defined region while understanding the impact on patient care.
- Provide evening or weekend after-hours on-call coverage as needed.
- Additional training in a medical or call-center environment.
- At least one year of experience equivalent to working in customer service.
About the company
NeoGenomics provides cancer-focused genetic testing and information services to help diagnose and guide treatment for various cancers. Its tests include cytogenetics, FISH, flow cytometry, IHC, ISH, and molecular testing, run in CAP-accredited and CLIA-certified laboratories across multiple U.S. sites. Healthcare providers use the tests for diagnosis and treatment planning, while pharmaceutical companies use the Pharma Services division for clinical trials and drug development, with partnerships like QIAGEN for companion diagnostics. The company aims to advance oncology diagnostics and personalized medicine by delivering accurate, actionable results and supporting new cancer therapies.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Fort Myers, Florida
Founded
2002
Get referred to NeoGenomics Laboratories
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 28, 2026 revenue rose 11% to $202 million, with NGS up 26%.
- August 26, 2026 Medicare expanded RaDaR ST coverage for immunotherapy response monitoring.
- June 2026 refinancing cut 2028 debt, while Q2 generated $20 million operating cash.
What critics are saying
- July 20, 2026 DOJ settlement exposed Laboratory Clinical Initiative kickback conduct through 2022.
- CMS coverage and payer policy still determine RaDaR ST and NGS reimbursement economics.
- Any future FCA violation or reimbursement denial would crush community-provider trust and volumes.
What makes NeoGenomics Laboratories unique
- July 2026 PTEN IHC CDx gives NeoGenomics an FDA-approved prostate companion diagnostic.
- NeoGenomics' nearly 500-test oncology menu standardizes community-provider workflows across diagnosis, therapy, and MRD.
- RaDaR ST and PanTracer Pro bundle genomic testing, reflex rules, and oncology interpretation.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Company Match
Employee Stock Purchase Plan
Tuition Reimbursement
Paid Vacation
Paid Holidays
Wellness Program
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 0%2 year growth
↑ 0%NeoGenomics highlights NGS, MRD growth strategy at Morgan Stanley Conference. NeoGenomics (NASDAQ:NEO) executives outlined the company's strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home. Speaking at the Morgan Stanley Healthcare Conference, Chief Executive Officer Tony Zook said the company remains focused exclusively on oncology and on serving community providers, where it estimates nearly 80% of patients receive treatment. NeoGenomics began with diagnostic testing but has expanded its portfolio to include therapy selection and MRD testing, he said. Zook said investors may underestimate the company's existing NGS business. Although NGS represents about 10% of NeoGenomics' test volume, it accounts for roughly one-third of clinical revenue, he said. The company's NGS portfolio exceeds $250 million in revenue and was growing 26%, according to Zook. Community oncology focus. Zook and Chief Operating Officer and President Warren Stone differentiated the company's approach to community oncology from that of providers focused on academic medical centers. Community physicians often operate under time constraints, see a broad range of cancer types and require practical, guideline-based testing workflows, the executives said. Stone said NeoGenomics offers nearly 500 tests spanning diagnosis, therapy selection, MRD, solid tumors and hematologic cancers. The breadth of that portfolio can allow providers to standardize their external testing with a single laboratory partner, he said. NeoGenomics is seeking to reduce administrative and clinical friction through care pathways and simplified ordering. Stone cited the company's PanTracer Pro offering, launched earlier this year, which enables physicians to provide a patient's cancer type and stage while NeoGenomics determines the appropriate testing approach based on guidelines and its OncoTree classification system. The resulting report can include potential therapy options and available clinical trials, Stone said. The company may also perform reflex testing or add-on testing where needed. "It's not distinct products. It's really around a workflow solution," Stone said of the PanTracer family, which includes tissue- and liquid-based offerings for solid-tumor therapy selection. NGS growth and revenue-cycle initiatives. Chief Financial Officer Abhishek Jain said NGS revenue increased 26% during the first half of 2026. Volume growth was in the mid-teens, with the remainder of the increase stemming from revenue-cycle-management, or RCM, initiatives. Jain said larger NGS panels are growing more than 20% as the company sees a shift away from single-gene and targeted panels. That mix shift has affected both volume metrics and average unit pricing, he said. * About two-thirds of NGS RCM growth came from the mix shift toward larger panels, according to Jain. * The remaining RCM growth came from contractual and policy wins, pricing actions, collection initiatives and commercial payer efforts. * More than 60% of clinical revenue is derived from direct client billing, Jain said. The company implemented the XiFin billing system in the third quarter of 2026. Jain said the platform is intended to improve collections processes and operational efficiency as NeoGenomics shifts toward more NGS and MRD testing. Looking ahead, Jain said investors should generally expect about half of the company's growth to come from volume and half from RCM on a go-forward basis. Zook said NGS and MRD could grow from about one-third of the business today to more than half over time, supporting both revenue and margin expansion. MRD and liquid biopsy opportunities. Stone said NeoGenomics' recently obtained coverage for immuno-oncology, or IO, applications of its RaDaR ST MRD test expands the company's addressable market by about $4 billion, out of an estimated $20 billion MRD market. The coverage also enables the company to present RaDaR as a pan-cancer offering, rather than one limited to specific indications, he said. According to Stone, RaDaR ST can detect disease at levels as low as one part per million and has a substantial body of peer-reviewed publications. NeoGenomics also has reorganized its commercial structure into separate pathology and oncology sales teams, with the oncology organization reaching what Stone described as a critical scale in July. For PanTracer LBx, the company's liquid-biopsy product, Zook said the key requirement for a more meaningful contribution is time. He said the liquid offering has complemented the broader PanTracer portfolio and helped support adoption of tissue-based testing. NeoGenomics expects liquid biopsy to become a substantial contributor in late 2027 and 2028, he said. Cash flow and capital allocation. Jain said NeoGenomics remains focused on becoming free-cash-flow positive for the full year. He cautioned that quarterly cash flow can be affected by timing factors, including payroll cycles and the cash payment related to a Department of Justice settlement in the third quarter. With most of its 2028 convertible notes refinanced, Jain said the company does not need major acquisitions to fill product portfolio gaps. Instead, he identified sales-force expansion, research and development, clinical studies, IT infrastructure and product platforms as key uses of capital. NeoGenomics has also said it plans to transition from the NovaSeq 6000 platform to NovaSeq X, an investment Jain said could support growth and operational efficiency. About NeoGenomics (NASDAQ:NEO). NeoGenomics, Inc is a provider of cancer-focused diagnostic testing and contract research services. The company operates clinical laboratories that support physicians, hospitals and other healthcare organizations with information used to help diagnose, classify and monitor cancer. Its testing services include anatomic pathology, immunohistochemistry, flow cytometry, cytogenetics, fluorescence in situ hybridization, molecular testing and next-generation sequencing. NeoGenomics also provides biopharmaceutical companies with clinical trial testing, central laboratory services, biomarker development and other research services intended to support the development of oncology therapies and companion diagnostics. Founded in 1999, NeoGenomics serves healthcare providers and pharmaceutical and biotechnology customers primarily in the United States, with additional capabilities supporting international clinical research programs.
NeoGenomics executives outlined the company's precision oncology growth strategy at the Morgan Stanley Healthcare Conference, emphasising next-generation sequencing and minimal residual disease testing. Chief executive officer Tony Zook said NGS represents about 10% of test volume but roughly one-third of clinical revenue, with revenue exceeding $250 million and growing 26%. Larger panels, revenue-cycle initiatives and payer actions are expected to drive future growth. The company is targeting community oncology providers, where an estimated 80% of patients receive treatment. Chief operating officer Warren Stone said NeoGenomics offers nearly 500 tests spanning diagnosis, therapy selection, MRD, solid tumours and haematologic cancers. Coverage for RaDaR ST's immuno-oncology applications increases the addressable market by approximately $4 billion, whilst PanTracer LBx is expected to become a substantial contributor in 2027–2028.
Why NeoGenomics (NEO) stock is up today. What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics NEOjumped 15.8% in the afternoon session after the company reported second-quarter 2026 earnings that surpassed Wall Street expectations and raised its full-year financial guidance. The cancer-diagnostics company posted adjusted earnings of $0.05 per share on revenue of $201.7 million, beating analyst forecasts of $0.03 per share and $197.3 million in revenue. The top-line result represented an 11.2% increase compared to the same period in the previous year. Following the strong performance, NeoGenomics lifted its full-year outlook, now expecting revenue of around $804 million. Furthermore, its adjusted earnings per share guidance for the full year of $0.19 also came in ahead of analyst estimates. What Is The Market Telling Us NeoGenomics's shares are very volatile and have had 28 moves greater than 5% over the last year. But moves this big are rare even for NeoGenomics and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 20 days ago when the stock gained 3.4% on the news that the company announced the launch of the first FDA-approved immunohistochemistry (IHC) companion diagnostic test for patients with prostate cancer. The test, called PTEN IHC CDx, is designed to identify PTEN protein loss in patients with prostate adenocarcinoma. This detection is crucial as it helps determine which patients may be eligible for AstraZeneca's recently approved targeted therapy, TRUQAP. By providing a necessary diagnostic tool for a specific, modern treatment, NeoGenomics has established a clear commercial application for its product, linking it directly to patient care decisions and a major pharmaceutical therapy. NeoGenomics is up 32.9% since the beginning of the year, and at $15.63 per share, it has set a new 52-week high. Despite the year-to-date gain, investors who bought $1,000 worth of NeoGenomics's shares 5 years ago would now be looking at only $342.08. ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you're unstoppable. These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same.
NeoGenomics lifts outlook as NGS Revenue jumps 26% and margins improve. 29 July 2026, 11:51 AM NGS growth and higher per-test revenue drive strong Q2 results. NeoGenomics (NASDAQ: NEO), a leader in oncology diagnostics, delivered a robust second quarter for 2026, with total revenue climbing 11% to $202 million. This performance was fueled by an impressive 26% year-over-year increase in next-generation sequencing (NGS) revenue, outpacing broader clinical services growth of 14%. The average revenue per clinical test rose sharply to $515 - up 12% over the prior year - despite only a modest 2% rise in clinical volume. | Key Metric | Q2 2026 | Q2 2025 | % Change | | Total Revenue | $202M | $181M | +11% | | NGS Revenue Growth | 26% | - | | Avg. Revenue per Test | $515 | $461 | +12% | | Clinical Test Volume | 363,498 | 356,630 | +2% | Operating leverage and margin expansion underpin profit reversal. Margin improvements were a standout, with gross profit up 19% to $92 million and adjusted EBITDA jumping 36% to $14 million. Key drivers were both the revenue mix shift to higher-margin NGS testing and disciplined expense controls: operating expenses fell 19% versus last year, largely on the back of avoiding prior-year impairment charges. Net income turned positive at $2 million, reversing a $45 million loss in the year ago quarter, though the quarter did include an $11 million gain from extinguishing debt. | Profitability Metric | Q2 2026 | Q2 2025 | % Change | | Gross Profit | $92M | $77M | +19% | | Gross Profit Margin (Adj.) | 48% | 45% | +2.6 pts | | Adjusted EBITDA | $14M | $11M | +36% | | Net Income | $2M | ($45M) | N/A | Guidance raised as NEO moves toward sustainable profitability. With business momentum accelerating, NeoGenomics raised its full-year 2026 outlook. The company now expects annual revenue of $802-$806 million - implying about 11% annual growth - and adjusted EBITDA of $56-$58 million, up more than 30% from last year. While a net GAAP loss is still forecasted for 2026 due to non-cash amortization and stock compensation, adjusted net income should be comfortably positive, as shown below: | 2026 Full-Year Outlook | Prior Guidance | Updated Guidance | Y/Y Change | | Revenue | $797-$803M | $802-$806M | +10-11% | | Adjusted EBITDA | $55-$57M | $56-$58M | +29-34% | | GAAP Net Loss | ($63M)-($50M) | ($42M)-($34M) | Improving | | Adjusted Net Income | Not previously disclosed | $22-$26M | - | Balance sheet fortified and commercial strategy refined. NeoGenomics ended the quarter with $146 million in cash and short-term investments after completing a $316 million offering of 0.75% convertible senior notes due 2032. A portion of the proceeds went toward retiring prior debt and mitigating dilution through capped call transactions, while $25 million was used for share repurchases. Operationally, the company launched a new dedicated commercial team for pathology and oncology, and advanced its RaDaR ST technology with additional Medicare reimbursement evidence submissions. Key takeaways: where does NEO go from here? The Q2 performance was underpinned by both top-line growth and expanding profit margins, thanks to mix shift toward higher-value genomic tests and cost efficiency. With revised guidance calling for double-digit revenue growth and a significant narrowing of losses, NeoGenomics appears to be executing on a strategy of sustainable, margin-driven expansion. While further profitability gains will depend on continued momentum in NGS and commercial execution, the company's reinforced balance sheet and raised outlook suggest that investors and analysts should monitor future volumes, per-test pricing, and reimbursement developments as key indicators of lasting value creation. For more details, readers can access the full results and financial filings on the NeoGenomics Investor Relations website. Contact Information: If you have feedback or concerns about the content, please feel free to reach out to Market Chameleon via email at [email protected]. About the Publisher - Marketchameleon.com: Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. Market Chameleon leverage extensive data, models, and analytics to provide valuable insights into these markets. Its primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards. NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com. The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information. Disclosure: This article was generated with the assistance of AI
NeoGenomics pays $9.8 million to settle kickback and Stark Law allegations. July 27, 2026 By: Allison Cook NeoGenomics Laboratories, a cancer-testing lab based in Fort Myers, Florida, has agreed to pay $9,813,260 to resolve False Claims Act allegations that it violated the Anti-Kickback Statute and the Stark Law, the Justice Department announced on July 20, 2026. The conduct ran from February 14, 2014, through December 31, 2022. Per the allegations, NeoGenomics gave 28 health care providers consulting help to build their own in-house testing labs and charged them less than that help was worth, allegedly to induce those providers to send lab work its way. It also paid outside consultants more when they steered more business to the lab, tying their compensation to the volume or value of referrals. Both arrangements funneled referrals that turned into Medicare and Medicaid claims, which the government treated as false. Of the $9.81 million, $6,542,173 is restitution. NeoGenomics self-reported the conduct through the HHS-OIG Provider Self-Disclosure Protocol on November 2, 2021, cooperated with the investigation, ended the arrangements, and received cooperation credit under the Justice Department's guidelines. The settlement is not an admission of liability. CONTACT US Please briefly describe the fraud you've observed, including who was involved, what happened, when it happened, where it happened, and how you know this information.